Leslie Aberman

No open positions remaining

Health Technology

Consumer Services

Commercial Services

Profile

Leslie Aberman worked as Senior Director-Intellectual Property at Seagen Inc. from 2015 to 2015.
Prior to that, Aberman worked as Associate General Counsel at Infectious Disease Research Institute.
Currently, Aberman is Vice President-Legal Affairs at Neoleukin Therapeutics, Inc. from 2019 to 2023.
Aberman completed an undergraduate degree at Brown University and a graduate degree at Columbia Law School.

Former positions of Leslie Aberman

Companies	Position	End
NEUROGENE INC.	General Counsel	2023-02-28
SEAGEN INC.	Corporate Officer/Principal	2015-02-28
Infectious Disease Research Institute Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases	General Counsel	-

See the detail of Leslie Aberman's experience

Training of Leslie Aberman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Leslie Aberman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Seagen, Inc. Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines	Health Technology
Brown University Brown University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Infectious Disease Research Institute Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases	Commercial Services
Columbia Law School Columbia Law School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity	Health Technology